Italia markets close in 1 hour 24 minutes
FTSE MIB
33.294,73 +386,68 (+1,18%) Dow Jones
38.825,54 +47,44 (+0,12%) Nasdaq
17.855,38 -1,64 (-0,01%) Nikkei 225
38.482,11 +379,67 (+1,00%) Petrolio
81,03 +0,70 (+0,87%) Bitcoin EUR
60.294,63 -291,95 (-0,48%)
NBIX Mar 2025 135.000 call
OPR - OPR Prezzo differito. Valuta in USD.
Aggiungi a watchlist
In data: 11:52AM EDT. Mercato aperto.
| Chiusura precedente | 20,96 |
| Aperto | 20,51 |
| Denaro | 18,00 |
| Domanda | 22,10 |
| Prezzo d'esercizio | 135,00 |
| Scadenza | 2025-03-21 |
| Min-Max giorno | 20,51 - 20,96 |
| Contratto - Min-Max | N/D |
| Volume | |
| Open Interest | 7 |
GlobeNewswireSosei Heptares’ partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117570 in Healthy Adults
NBI-1117570 is an investigational, oral, muscarinic M1/M4 selective dual agonist discovered by Sosei Heptares that may have the potential to treat neurological and neuropsychiatric conditionsNBI-1117570 is the second compound to advance into clinical development from a portfolio of selective muscarinic receptor agonists licensed by Sosei Heptares to Neurocrine following NBI-1117568, an oral, selective muscarinic M4 receptor agonist, which is in Phase 2 clinical trials as an investigational treat
© 2024 Yahoo. Tutti i diritti riservati.